Aviva
HZNP

Aviva’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Aviva’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-32,349
Closed -$3.74M – 1041
2023
Q3 		$3.74M Buy
32,349
+8,646
+36% +$929K 0.02% 544
2023
Q2 		$2.44M Sell
23,703
-141,111
-86% -$14.9M 0.01% 598
2023
Q1 		$18M Sell
164,814
-178,612
-52% -$19.7M 0.08% 360
2022
Q4 		$39.1M Buy
343,426
+24,062
+8% +$2M 0.19% 117
2022
Q3 		$19.8M Buy
319,364
+57,497
+22% +$4.02M 0.11% 243
2022
Q2 		$20.9M Buy
261,867
+105,274
+67% +$9.97M 0.11% 242
2022
Q1 		$16.5M Buy
156,593
+79,185
+102% +$7.72M 0.08% 297
2021
Q4 		$8.34M Buy
77,408
+9
+0% +$982 0.04% 448
2021
Q3 		$8.48M Buy
77,399
+7,139
+10% +$741K 0.04% 441
2021
Q2 		$6.58M Buy
70,260
+5,557
+9% +$511K 0.03% 509
2021
Q1 		$5.96M Buy
+64,703
New +$5.46M 0.03% 482

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Aviva's HZNP Position: Q4 2023 in Review

Aviva sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 32,349 shares — an estimated $3.74M sold.

Aviva first reported a position in HZNP in Q1 2021 and held it in 11 quarters. The position peaked at $39.1M in Q4 2022. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Aviva reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Aviva sold 32,349 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $3.74M.
  • Aviva first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 11 quarters.
  • Aviva's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $39.1M in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Aviva's 13F filing for Q4 2023, filed 9 Feb 2024.